Influence of hepatitis C virus coinfection on failure of HIV-infected patients receiving highly active antiretroviral therapy to achieve normal serum beta2microglobulin levels

J A García-García; J A Mira; J Fernández-Rivera; A J Ramos; J Vargas; J Macías; J A Pineda

doi:10.1007/s10096-003-0888-4

Influence of hepatitis C virus coinfection on failure of HIV-infected patients receiving highly active antiretroviral therapy to achieve normal serum beta2microglobulin levels

Eur J Clin Microbiol Infect Dis. 2003 Mar;22(3):194-6. doi: 10.1007/s10096-003-0888-4. Epub 2003 Mar 1.

Authors

J A García-García¹, J A Mira, J Fernández-Rivera, A J Ramos, J Vargas, J Macías, J A Pineda

Affiliation

¹ Departamento de Medicina Interna, Hospital Universitario de Valme, Carretera de Cádiz s/n, 41014, Sevilla, Spain.

PMID: 12649720
DOI: 10.1007/s10096-003-0888-4

Abstract

The influence of hepatitis C virus (HCV) coinfection on the kinetics of serum beta2microglobulin levels in HIV-infected patients undergoing highly active antiretroviral therapy was analyzed. After 96 weeks of therapy, beta2microglobulin levels declined significantly both in 24 HCV seronegative and 16 HCV-infected individuals. Throughout the follow-up period, HCV-infected patients showed higher beta2microglobulin values than non-HCV-infected patients. These results show that HCV infection precludes immune deactivation in HIV-infected patients undergoing highly active antiretroviral therapy.

Publication types

Clinical Trial

MeSH terms

Antiretroviral Therapy, Highly Active* / methods
Female
HIV Infections / blood
HIV Infections / complications*
HIV Infections / drug therapy*
HIV Infections / immunology
Hepatitis C / complications*
Hepatitis C / diagnosis
Hepatitis C / immunology
Humans
Male
Prospective Studies
RNA, Viral / analysis
Treatment Failure
Viral Load / trends
beta 2-Microglobulin / blood*

Substances

RNA, Viral
beta 2-Microglobulin